12. Before we decide if we should do a detailed investigation of a complaint, we look at whether there are signs the organisation has got something wrong. We do this by comparing what should have happened with what did happen. We have done this and have not seen any signs that something has gone wrong.
13. There is no guidance that requires, or recommends, pharmacists to tell patients when giving them different brands of medication. There is also no guidance on this when prescribing levothyroxine. Brand information is usually available to the patient as the packaging will have the brand name on it. The patient would have this information when discussing medication with their GP.
14. It is not usual practice, or a requirement, for a pharmacy to get levothyroxine from the same supplier all the time. Generic prescribing of levothyroxine medication is recommended so changes in brand are normal, as advised in the statement from the BTA. Sometimes there is limited availability so it is reasonable for pharmacists to stock what is available. This allows for a quicker medicine supply as advised in the NHS guidance.
15. The patient.info website says if generic medicine is prescribed, a pharmacist can dispense any suitable available product to the patient. The BTA statement does say some patients may need to be prescribed a specific brand due to intolerance. It is the responsibility of the patient’s GP (the prescriber) to prescribe a specific brand if needed.
16. We cannot see that Ms A’s GP had prescribed a specific brand of levothyroxine medication. So it was appropriate for the pharmacy to give Ms A different brands and it was not required to tell her.
17. The GOV.UK guidance on levothyroxine says if a patient reports symptoms after their brand is changed, healthcare professionals are advised to consider testing of thyroid function and follow the ‘advice for healthcare professionals’ section. This says if a patient keeps getting symptoms after switching products, to consider prescribing a specific levothyroxine product known to be suitable for the patient. It says if symptoms continue to consider prescribing levothyroxine in an oral form. As we mention above, the GP is the prescriber so this is something Ms A’s GP would have needed to do. The pharmacist is not the prescriber.
18. We have not seen signs that the pharmacy got things wrong and we cannot say it should have told Ms A when it was giving her different brands of levothyroxine.
19. We appreciate how difficult things have been for Ms A when experiencing side effects to her medication. We hope she does not feel our decision reduces the impact of what she has been through and that she can understand why we cannot hold the pharmacy responsible for her experience.